TD Asset Management Inc Buys 61,764 Shares of Medpace Holdings, Inc. $MEDP

TD Asset Management Inc raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 457,645 shares of the company’s stock after purchasing an additional 61,764 shares during the period. TD Asset Management Inc owned 1.63% of Medpace worth $143,636,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Verdence Capital Advisors LLC raised its position in Medpace by 5.7% during the 2nd quarter. Verdence Capital Advisors LLC now owns 1,049 shares of the company’s stock worth $329,000 after purchasing an additional 57 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in Medpace by 8.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 3,749 shares of the company’s stock worth $1,177,000 after acquiring an additional 299 shares during the period. Johnson Investment Counsel Inc. grew its holdings in Medpace by 9.8% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 1,647 shares of the company’s stock worth $517,000 after acquiring an additional 147 shares during the period. PDS Planning Inc grew its holdings in Medpace by 1.5% during the 2nd quarter. PDS Planning Inc now owns 2,421 shares of the company’s stock worth $760,000 after acquiring an additional 35 shares during the period. Finally, Blue Trust Inc. grew its holdings in Medpace by 10.5% during the 2nd quarter. Blue Trust Inc. now owns 516 shares of the company’s stock worth $162,000 after acquiring an additional 49 shares during the period. 77.98% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO August J. Troendle sold 48,487 shares of the firm’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the transaction, the chief executive officer owned 962,615 shares of the company’s stock, valued at approximately $434,803,569.35. This trade represents a 4.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the firm’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the general counsel directly owned 10,343 shares in the company, valued at approximately $4,654,350. The trade was a 22.48% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 161,266 shares of company stock worth $74,111,427 in the last 90 days. Company insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on MEDP shares. UBS Group downgraded Medpace from a “neutral” rating to a “sell” rating and increased their price target for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Jefferies Financial Group increased their price target on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a report on Tuesday, September 9th. TD Cowen reiterated a “sell” rating and set a $366.00 price target (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Finally, Robert W. Baird raised their target price on Medpace from $313.00 to $490.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Medpace currently has an average rating of “Reduce” and an average price target of $424.10.

Medpace Price Performance

Shares of MEDP opened at $516.93 on Wednesday. The stock has a 50-day moving average of $486.83 and a 200-day moving average of $377.81. The company has a market cap of $14.52 billion, a PE ratio of 38.43, a P/E/G ratio of 3.31 and a beta of 1.40. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $547.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business had revenue of $603.31 million for the quarter, compared to analysts’ expectations of $537.70 million. During the same quarter last year, the firm earned $2.75 EPS. The firm’s revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.